Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma
Language English Country Great Britain, England Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
19093260
DOI
10.1080/07357900802098165
PII: 906934442
Knihovny.cz E-resources
- MeSH
- Ki-67 Antigen analysis MeSH
- Antigens, CD analysis MeSH
- Adult MeSH
- Immunohistochemistry MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Biomarkers, Tumor analysis MeSH
- Breast Neoplasms drug therapy pathology MeSH
- Neoadjuvant Therapy methods MeSH
- Lymphocyte Count MeSH
- Predictive Value of Tests MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Lymphocytes, Tumor-Infiltrating pathology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Ki-67 Antigen MeSH
- Antigens, CD MeSH
- Biomarkers, Tumor MeSH
Tumor-infiltrating leukocytes and other immunohistochemical parameters were evaluated in pretherapeutic biopsies and resection specimens in 73 patients undergoing neoadjuvant chemotherapy with doxorubicin and paclitaxel. Ten patients with pathological complete response had significantly higher p53 expression, CD3(+) lymphocyte and CD83(+) cell counts, and lower progesterone receptor expression. In the remaining 63 patients, a significant decrease in the percentage of Ki-67, vascular endothelial growth factor expression, CD68(+) monocytes, and increased CD31(+), CD34(+), and SMA(+) stromal vessels, maximal CD3(+) and CD56(+) lymphocyte, maximal and mean CD83(+) cell, maximal CD1a(+), and maximal and mean S100(+) cell counts were observed after neoadjuvant chemotherapy.
References provided by Crossref.org
Neopterin as a biomarker of immune response in cancer patients
